Maharashtra FDA Cracks Down On Blood Centres

In a significant move to guarantee the availability of safe blood and blood components, the Maharashtra Food and Drug Administration (FDA) has suspended the licences of 34 blood centres and blood storage facilities. This action was taken between April and June 2026 due to violations of the Drugs and Cosmetics Act, 1940, and related rules.

The state of Maharashtra currently has 413 licensed blood centres and 468 blood storage centres, all of which are subject to mandatory annual inspections and surprise checks by the FDA. During these inspections, 21 blood centres and 13 blood storage centres had their licences suspended. Furthermore, two blood centres and two blood storage centres lost their licences permanently after inspectors found serious irregularities.

These irregularities included non-compliance with quality standards, deficiencies in record-keeping, breaches of licence conditions, and lapses in quality management systems. The permanent cancellations of licences affected facilities such as Patil Hospital Blood Storage Centre in Bori Pardhi, Pune, and Aadhar Blood Storage Centre (Trust) in Bhiwandi, Thane district.

In addition to the suspensions and cancellations, the FDA also cancelled the licences of two blood centres in June following complaints and subsequent inspections. These included Maya Blood Centre and Sir J.J. Municipal Blood Centre in Mumbai. The regulator emphasized that serious violations detected at these facilities could adversely affect the safety, quality, and efficacy of blood and blood components, potentially endangering both blood donors and patients.

FDA Commissioner Tukaram Mundhe stated that ensuring the availability of safe and quality blood and blood components is the regulator's highest responsibility. He warned that blood collection, processing, and distribution cannot be treated as a commercial activity and that no leniency would be shown towards institutions compromising patient safety for financial gain.

The FDA has assured that regular and surprise inspections of all blood centres and blood storage facilities across Maharashtra will continue. Strict legal action will be initiated against institutions found violating the prescribed norms. This crackdown aims to maintain the highest standards of safety and quality in the blood supply chain, ultimately protecting the health and well-being of patients and blood donors.

The Maharashtra FDA's actions demonstrate a commitment to upholding the integrity of the blood supply system. By taking strict measures against non-compliant facilities, the regulator is sending a strong message about the importance of prioritizing patient safety and adhering to regulatory standards.

In the context of the state's healthcare system, this move is significant. It highlights the need for constant vigilance and monitoring to ensure that blood centres and storage facilities operate in accordance with the law and maintain the highest standards of quality and safety.

The impact of this crackdown will be felt across the state, as patients and blood donors can now have greater confidence in the safety and efficacy of the blood supply. As the FDA continues its inspections and enforcement actions, it is clear that the regulator is dedicated to protecting the public's health and well-being.

In conclusion, the Maharashtra FDA's decision to suspend and cancel licences of blood centres and storage facilities is a crucial step in maintaining the integrity of the blood supply chain. This action underscores the importance of prioritizing patient safety and adhering to regulatory standards, ultimately contributing to a safer and more reliable healthcare system for the people of Maharashtra.